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In mammals, different genes encode two closely relatedStation Biologique, B.P. 74
glycogen synthase kinase-3 (GSK-3) enzymes, GSK-329682 Roscoff cedex
and GSK-3. The discovery of GSK-3 functions in WntBretagne
signal-transducing pathways, insulin action, apoptosis,France
and circadian rhythm, the deciphering of unique regula-2 Laboratory of Molecular & Cellular Neuroscience
tion mechanisms of GSK-3 (inhibitory phosphorylation3 Laboratory of Molecular Embryology
on Ser9, priming of substrate by phosphorylation byThe Rockefeller University
another kinase), the determination of the crystal struc-1230 York Avenue
ture of human GSK-3, and the clear implication ofNew York, New York 10021
GSK-3 in various human diseases (diabetes, Alzheimer’s4 Division of Pharmacognosy and Natural
disease, cancers) have all recently contributed to a re-Products Chemistry
newed interest in this kinase (for reviews see [1–5].Department of Pharmacy
Growing evidence supports the view that GSK-3 acti-University of Athens
vation [6, 7] and nuclear translocation [8] are a prerequi-Panepistimiopolis Zografou
site for neuronal apoptosis. The data stem from cellGR-15771 Athens
culture experiments in which apoptosis induced by vari-Greece
ous agents can be prevented in several ways, leading5 Structural Biology Unit
to GSK-3 inactivation: (1) overexpression of FRAT1, aDepartment of Experimental Oncology
negative regulator of GSK-3, confers resistance of PC12European Institute of Oncology
cells to apoptosis [9, 10]; (2) pharmacological inhibitorsVia Ripamonti 435
of GSK-3 prevent apoptosis in PC12 cells [10–12], hu-20141 Milano
man SH-SY5Y neuroblastoma cells [13, 14], and a Hun-Italy
tington disease cell model [15]; (3) activation of Wnt6 Centre for Structural Biology
signaling (and therefore GSK-3 inhibition) preventsInstitute of Cancer Research
c-Myc-induced apoptosis in Rat-1 cells [16]; (4) expres-Chester Beatty Laboratories
sion of a kinase-deficient GSK-3 reduces cell death237 Fulham Road
induced by Akt inhibition [9]; (5) FGF (which activatesLondon SW3 6JB
Akt and thus inhibits GSK-3) reduces cell death inducedUnited Kingdom
by glutamate [17], while overexpression of GSK-3 in-
creases cell death; and (6) inhibition of GSK-3 by Ser9
phosphorylation by PKA is associated with neuronal
Summary survival [18]. In addition to these in vitro data, two animal
models reinforce the link between GSK-3 activation and
Gastropod mollusks have been used for over 2500 apoptosis: (1) conditional transgenic mice overexpress-
years to produce the “Tyrian purple” dye made famous ing GSK-3 in brain during adulthood show signs of neu-
by the Phoenicians. This dye is constituted of mixed ronal stress and apoptosis [19], and (2) expression of
bromine-substituted indigo and indirubin isomers. shaggy, the Drosophila homolog of GSK-3, enhances
Among these, the new natural product 6-bromoindiru- the neurodegeneration induced by expression of human
bin and its synthetic, cell-permeable derivative, 6-bro- Tau in flies, while expression of a loss-of-function mu-
moindirubin-3-oxime (BIO), display remarkable selec- tant of shaggy prevents this neurodegeneration [20].
tive inhibition of glycogen synthase kinase-3 (GSK-3). Only a very limited number of pharmacological inhibi-
Cocrystal structure of GSK-3/BIO and CDK5/p25/ tors of GSK-3 are available [21], lithium being the most
indirubin-3-oxime were resolved, providing a detailed frequently used [22] despite its effects being in the 10–20
view of indirubins’ interactions within the ATP binding mM range and its demonstrated effect on inositol phos-
pocket of these kinases. BIO but not 1-methyl-BIO, its phatases [23]. Recently, we noted that several pharma-
kinase inactive analog, also inhibited the phosphoryla- cological inhibitors of cyclin-dependent kinases (CDKs)
tion on Tyr276/216, a GSK-3/ activation site. BIO were in fact quite potent on GSK-3 [24, 25]. Among these
is a family of bis-indoles known as indirubins, initially
identified as CDK inhibitors [26, 27]. Indirubins derive*Correspondence: meijer@sb-roscoff.fr
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from the spontaneous, nonenzymatic dimerization of exposed to sunlight to generate the expected Tyrian
isatin and indoxyl, two colorless precursors found either purple dye (Figure 1). The mollusks were then frozen
free or conjugated to carbohydrates, which are found and lyophilized prior to extraction by dichloromethane.
in over 200 species of indigo-producing plants [28, 29]. Organic phase soluble indigoids were resolved by silica
Although they constitute minor side products, indirubins gel chromatography. Indigo derivatives were discarded,
contribute by their red color to the unique blue-purplish and indirubins (0.000025%) were further separated by
color of natural indigo that distinguishes it from synthetic MPLC and identified by 1D and 2D NMR and mass spec-
indigo. Indirubins, along with indigo, are also produced trometry as indirubin (1), 6-bromoindirubin (2), 6-bro-
by various bacterial strains (reviewed in [30, 31]) and by moindirubin (3), and 6,6-dibromoindirubin (4) (Figure 1).
a number of gastropod mollusks [32]. Moreover, they 6-bromoindirubin (3) has never been isolated from any
can be found in urine from diseased and healthy patients Muricidae or Thaididae gastropod or from any other
([33] and references therein). Indirubin constitutes the natural source [32]. Each of these compounds was syn-
main active ingredient of a traditional Chinese medicinal thesized, along with its corresponding 3-oxime deriva-
recipe, Danggui Longhui Wan, used to treat various dis- tive (5–8), as this modification enhances solubility, ki-
eases including chronic myelocytic leukemia [34, 35]. nase inhibition, and cell permeability [24, 26]. 1-methyl
Indirubin and indigo have been recently discovered as derivatives (9–11) were also synthesized, as they were
potent ligands of the aryl hydrocarbon receptor (AhR), expected, from previous CDK2/indirubin cocrystal struc-
also known as the “dioxin receptor” [33] (M.K. et al., tures [26, 27], to provide kinase inactive control com-
submitted). pounds. Finally, 3-oxime in compound (7) was also re-
Gastropods of the Muricidae and Thaididae families placed by 3-methoxime (12) or 3-acetoxime (13). We
have been used in various parts of the world as the next evaluated the effects of these compounds on puri-
source of a vivid purplish-red dye known as “Tyrian fied GSK-3/, CDK1/cyclin B, and CDK5/p25 (Table
purple” or “royal blue” around the Mediterranean sea 1A). As expected, indirubin (1) was active on GSK-3/
[32]. The highly prized, beautiful Tyrian purple, obtained and on CDKs (10-fold less). Although a 6-bromo substi-
at great expense essentially from the two species Murex tution (2) led to reduced kinase inhibition, the 6-bromo
brandaris and Hexaplex trunculus, was the object of an substitution (3) greatly enhanced the selectivity for
important trade in Crete (5th century BC), Phoenicia, GSK-3 over CDKs. Addition of a 3-oxime substitution
Greece, and later in Rome. The color was considered a
(5–8) led to an overall increase in kinase inhibitory effects
privilege of the emperors Nero and Caligula. In Britain
and increased solubility, although the selectivity for
and Ireland, the dog whelk (Nucella lapillus) was also
GSK-3 was slightly reduced. The 6-bromoindirubinsused for many years as a source of purple dye. Other
substituted on 3 by methoxime (12) or acetoxime (13)dye-producing mollusks include Purpura pansa (Mex-
were also quite potent and GSK-3 selective (but lessico, Pacific Ocean), Purpura patula (Mexico, Atlantic
soluble, which precluded their use in cells). As expected,Ocean), and Rapana venosa (Japan). The hypobranchial
methylation on position N1 inactivated the indirubinsgland of these gastropods contains colorless precur-
(9–11) as kinase inhibitors.sors, indoxyl-sulfate, its mercaptan derivative, and their
bromo derivatives, which release various indoxyls upon
maceration (in fact hydrolysis by purpurase). When ex- 6-Bromoindirubins Are Selective
posed to light and oxygen, these indols dimerize in a Inhibitors of GSK-3
mixture of indigo and indirubin, mainly 6,6-dibromo- We next tested BIO (7) and methoxime and acetoxime
indigo. Paul Friedlander was the first to determine the (12, 13) on a series of 20 purified protein kinases assayed
composition of the dye from Murex brandaris, in 1909, in the presence of 15 M ATP. The results of these
from 1.4 g of dye isolated from 12,000 mollusks [36]. assays confirm the strong selectivity of 6-bromo-substi-
The famous “Tekhelet” described in the Bible was also tuted indirubins for GSK-3/ (Table 1B). An acetoxime
identified as a mixture of indigoids specifically obtained or methoxime substitution on position N3 further con-
from Hexaplex trunculus [32, 37]. tributes to the GSK-3 selectivity. As an alternative ap-
In an effort to identify new kinase inhibitors with in- proach to evaluate the selectivity of BIO, we immobilized
creased potency and selectivity, we investigated the indirubin-3-oxime on Affigel beads through a polyethyl-
natural indirubins produced by the Mediterranean mol- ene linker attached at the 3 position (Figures 2A and
lusk Hexaplex trunculus. Beside the dominant bromo- 2B). A porcine brain extract was then run on these beads
indigos, we identified various bromo-substituted indiru- in the absence or presence of free BIO, and the bound
bins, and one of them, 6-bromoindirubin, which was proteins were resolved by SDS-PAGE followed by silver
isolated for the first time as a natural product, turned out staining and anti-GSK-3 Western blotting (Figures 2C
to be a potent GSK-3 inhibitor. Its synthetic derivative, and 2D). Although a large number of proteins were found
6-bromoindirubin-3-oxime (BIO), and related analogs to bind to indirubin beads, the presence of free BIO
constitute unique cell-permeable and selective inhibi- did not lead to major changes in the overall pattern
tors of GSK-3. We here provide the first cocrystal struc- of indirubin binding proteins. However, it completely
tures of GSK-3 and CDK5 with an inhibitor.
prevented the binding of GSK-3/.
Results
Cocrystal Structure of BIO with GSK-3
We next attempted to soak BIO into a GSK-3 crystal,Purification, Identification, and Kinase Inhibitory
the structure of which had recently been describedProperties of Shellfish Indirubins
[38, 39]. A cocrystal structure was obtained with 2.8 A˚Sixty kilograms of Hexaplex trunculus were collected,
and the animals were extracted from the shells and resolution (Figure 3). The overall structure of GSK-3/
Tyrian Purple-Derived Indirubins Inhibit GSK-3
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Figure 1. Tyrian Purple Constituents and Chemically Synthesized Indirubin Analogs
Hexaplex trunculus (A) was extracted for Tyrian purple (B), various brominated indirubins (1–4) (C), and indigos. Oxime derivatives (5–8) and
N1-methylated analogs (9–11) of these indirubins were synthesized, as well as the methoxime and acetoxime of 6-bromoindirubin (12, 13).
6-bromoindirubin-3-oxime (BIO) (7) and its control analog 1-methyl-6-bromoindirubin-3-oxime (MeBIO) (11) were used in the biological
models.
BIO is basically identical to the GSK-3 structure. The between the inhibitor-bound and the native complex. An
“omit” map shows clear electron density for all inhibitorsmall N-terminal lobe of GSK-3 consists predominantly
of  sheets, while the C-terminal lobe is predominantly atoms (Figure 4B). IO binds in the ATP binding pocket
of CDK5. The double-ring system of IO is inserted in a-helical (Figure 3A). BIO is located in the ATP binding
pocket (Figure 3B). BIO binds in a planar conformation hydrophobic pocket formed by CDK5 residues Ile10,
Val18, Ala31, Val64, Phe80, Leu133, and the alkyl portioninto a narrow hydrophobic pocket whose faces are de-
fined by Ile62, Val70, Ala83, Leu132, and Tyr134 on one of Asn144, and several van der Waals contacts are ob-
served. In addition, three hydrogen bonds are formedside and Thr138, Arg141, Leu188, and Cys199 on the
other. As observed with CDK5-bound indirubin (see be- with the backbone of CDK5. The N1 cyclic nitrogen
donates a hydrogen bond to the carbonyl oxygen oflow), all direct hydrogen bonding interactions between
BIO and the protein are made to the peptide backbone Cys83CDK5, the carbonyl oxygen of the lactamic ring binds
the backbone amide of Cys83CDK5, and the N1 lactamonly and do not involve protein side chains. The cyclic
nitrogen of the pyrole ring donates a hydrogen bond to amide nitrogen donates a hydrogen bond to the peptide
oxygen of Glu81CDK5 (Figure 4C). We next compared thethe peptide carbonyl oxygen of Val135, while the cyclic
nitrogen of the lactam ring donates a hydrogen bond to CDK5 region involved in IO binding with the equivalent
CDK2 region of the CDK2/cyclinA/indirubin-5-sulpho-the carbonyl oxygen of Asp133, and the lactam carbonyl
oxygen accepts a hydrogen bond from the backbone nate (I5S) structure [27]. As shown in Figure 4D, the
aromatic ring systems of both compounds occupy theamide of Val135. As with CDK5, the bond to the back-
bone amide is quite short at around 2.4 A˚. The prefer- same position in the two structures. This position pro-
vides optimal shape complementarity with the ATP bind-ence of BIO for binding to GSK-3 as compared to CDKs
can be explained by the presence of Leu132 in GSK- ing cleft while allowing the formation of three hydrogen
bonds with the backbone of residues 81 and 83. How-3, which is in van der Waals contact with the bromine
at one end of the pocket. In CDK2 and CDK5, the equiva- ever, while the oxime group of IO makes no direct inter-
actions with CDK5, the sulphonate group of I5S formslent residue is a phenylalanine whose greater bulk would
significantly hinder the binding of a bromine substituent a salt bridge with Lys33CDK2 and a hydrogen bond with
the backbone nitrogen of Asp145CDK2. These additionalat this position.
interactions may explain the higher affinity of I5S for
both CDK5/p35 and CDK2/cyclinA (with IC50 values ofCocrystal Structure of IO with CDK5/p25
0.06 M and 0.03 M, respectively) relative to IO (0.10As a complement to the CDK2/ indirubin cocrystal struc-
M and 0.44 M, respectively) [26]. The nearly identicaltures [26, 27] and for comparison, indirubin-3-oxime
orientation of these inhibitors indicates that the effect(IO) (5) was cocrystallized with CDK5/p25, another major
of substitutions at the C3 and C5 positions may bebrain protein kinase involved, along with GSK-3, in the
additive, suggesting a strategy for further improvementabnormal phosphorylation of tau in Alzheimer’s disease.
of these inhibitors.The overall structure of the CDK5/p25-IO complex is
basically identical to the CDK5/p25 structure [40] (Figure
4A). The small N-terminal lobe of CDK5 consists predomi- 6-Bromoindirubins Behave as GSK-3
Inhibitors in Cellsnantly of  sheets, while the C-terminal lobe is predomi-
nantly -helical (Figure 4A). There are no significant dif- To test whether BIO behaved as a GSK-3 modulator
in a cellular context, we measured its effects on theferences in the reciprocal orientation of these lobes
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Table 1. Selectivity of Tyrian Purple-Derived Indirubins
A. Effect of Indirubins on CDK1/Cyclin B, CDK5/p25, and GSK-3 Kinase Activitiesa
No. Compound GSK-3 / CDK1/Cyclin B CDK5/p25
1 indirubin 1.00 10.00 10.00
2 6-bromoindirubin 22.00 100.00 100.00
3 6-bromoindirubin 0.045 90.00 53.00
4 6,6-dibromoindirubin 4.50 100.00 100.00
5 indirubin-3-oxime (IO) 0.022 0.18 0.10
6 6-bromoindirubin-3-oxime 0.34 3.00 1.20
7 6-bromoindirubin-3-oxime (BIO) 0.005 0.32 0.083
8 6,6-dibromoindirubin-3-oxime 0.12 17.00 1.30
9 1-methyl-indirubin-3-oxime (MeIO) 100.00 73.00 100.00
10 1-methyl-6-bromoindirubin 100.00 80.00 100.00
11 1-methyl-6-bromoindirubin-3-oxime (MeBIO) 44.00 55.00 100.00
12 6-bromoindirubin-3-methoxime 0.03 3.40 2.20
13 6-bromoindirubin-3-acetoxime 0.01 63.00 2.40
B. Selectivity of 6-Bromoindirubinsb
Protein Kinases 5 (IO)c 7 (BIO) 12 13
GSK-3/ 0.022 0.005 0.030 0.010
CDK1/cyclin B 0.18 0.32 3.40 63
CDK2/cyclin A 0.44 0.30 15 4.3
CDK4/cyclin D1 3.33 10 10 10
CDK5/p35 0.10 0.08 2.20 2.4
erk1 100 10 10 10
erk2 100 10 10 10
MAPKK 100 10 10 10
protein kinase C  27 12 10 10
protein kinase C 1 4 10 10 10
protein kinase C 2 20 10 10 10
protein kinase C  8.40 10 10 10
protein kinase C  100 10 10 10
protein kinase C  20 10 10 10
protein kinase C 	 52 10 10 10
protein kinase C 
 100 10 10 10
cAMP-dependent PK 6.3 10 10 10
cGMP-dependent PK 9 10 10 10
casein kinase 2 12 10 9 10
insulin receptor Tyr kinase 11 10 10 10
a A series of indirubin analogs were tested at various concentrations in three kinase assays, as described in Experimental Procedures. IC50
values were calculated from the dose-response curves and are reported in M.
b Kinases were assayed in the presence of various concentrations of each compound. IC50 values, determined from the dose-response curves,
are expressed in M.
c Data from [26].
phosphorylation of specific GSK-3 substrates. First, we compared to BIO, and therefore to its binding to alterna-
tive targets.made use of the monoclonal ABC antibody, a dephos-
pho-specific antibody that crossreacts with -catenin Indirubins have recently been described to interact
with AhR [33]. To rule out the possibility that BIO-when it is not phosphorylated by GSK-3 (on either Ser37
or Thr41) [41]. This antibody thus provides a convenient induced -catenin dephosphorylation/stabilization was
due to an indirect, AhR-dependent effect, we made usepositive signal on Western blots when GSK-3 is inhib-
ited. We also made use of a general anti--catenin anti- of cell lines deficient either in AhR or ARNT (a cotran-
scriptional factor of AhR) [43]. BIO triggered a robustbody, as inhibition of -catenin phosphorylation leads
to its stabilization [42]. COS-1 cells were exposed for -catenin stabilization in both cell lines (Figure 5B). Fur-
thermore, although MeBIO is a potent AhR agonist (M.K.24 hr to various indirubins or to LiCl, and their levels of
unphosphorylated -catenin, total -catenin, and total et al., submitted), MeBIO is inactive on GSK-3 (Table
1A) and on cellular -catenin phosphorylation/stabiliza-GSK-3 were examined by Western blotting (Figure 5A).
BIO and LiCl treatment, but neither the kinase-inactive tion (Figure 5). Altogether, these data demonstrate that
BIO acts by a direct effect on GSK-3 rather than throughMeBIO nor IO, led to a major increase of the unphos-
phorylated -catenin level. This was also accompanied an indirect, AhR-dependent pathway.
GSK-3 and GSK-3 activity are enhanced by theby a modest increase in total -catenin level, as ex-
pected from the dephosphorylation-dependent increased phosphorylation of a specific tyrosine residue (Tyr276
and Tyr216, respectively) [44, 45]. The tyrosine kinasehalf-life of -catenin. BIO thus acted as a true GSK-3
inhibitor in this cell line. The apparent lack of effect of responsible for this phosphorylation in mammals is yet
unknown, but there is some evidence that it indirectlyIO in this cell line may be due to its reduced specificity
Tyrian Purple-Derived Indirubins Inhibit GSK-3
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Figure 2. BIO Is a Selective GSK-3 Inhibitor In Vitro
Indirubin was immobilized on Affigel through a linker (A). Indirubin beads (B) and control ethanolamine beads were exposed to a porcine brain
lysate in the presence () or absence () of 20 M BIO. Following stringent washing, the bound proteins were analyzed by SDS-PAGE followed
by silver staining (C) or Western blotting with anti-GSK-3 antibody (D).
depends on GSK-3 activity [11, 46]. We therefore investi- plants treated with LiCl (Figure 6H, lane 3) or BIO (lane
4) shows induction of both genes. This effect was resis-gated the effect of indirubins on this key tyrosine phos-
phorylation. SH-SY5Y cells were exposed to IO, MeIO, tant to injection of RNA encoding the Wnt inhibitor axin
(Figure 6H, lanes 9 and 10), which requires GSK-3 forBIO, and MeBIO for 12 hr, and the phosphorylation of
Tyr276 (GSK-3) and Tyr216 (GSK-3) was estimated its activity, but not to a dominant-negative Tcf molecule
(DN Xtcf-3) [50] (lanes 6 and 7) which blocks the pathwayby Western blotting with phospho-specific antibodies.
As little as 1 M IO and BIO dramatically reduced the downstream of GSK-3 (Figure 6A). Another outcome of
ectopic Wnt pathway activation in Xenopus is the indi-level of tyrosine phosphorylation of both GSK-3 isoforms
(Figure 5C). This was accompanied, as expected, by an rect induction of neural tissue in animal cap explants
[51]. We compared such explants from embryos treatedincreased level in total GSK-3, total -catenin, and
dephospho--catenin. None of these changes were ob- with LiCl (Figure 6I, lanes 4 and 5), BIO (lanes 6 and 7),
or injected with RNA for the neuralizing factor nogginserved with MeIO and MeBIO.
(lane 3) by RT-PCR for various neural and anterior mark-
ers. BIO had the strongest effect on anterior markers6-Bromoindirubins Behave as GSK-3
like the neural gene otx2 and the cement gland markerInhibitors In Vivo
xag1 even at the lowest concentration tested (5 M). WeWe then investigated the in vivo effect of BIO in a well-
conclude that BIO is an effective and specific inhibitorknown developmental system. GSK-3 is a component
of GSK-3 activity in vivo, with higher specific activityof the Wnt signal transduction pathway, where its phos-
than LiCl.phorylation of -catenin inhibits signaling in the absence
of Wnt ligand (Figure 6A) [42]. In Xenopus laevis em-
bryos, maternal Wnt activity is necessary for dorsal axis Discussion
formation, while inhibition of zygotic Wnt activity is re-
quired for head formation [47]. We compared the pheno- Indirubins have been known for over a century as a
contaminant of the plant-derived indigo dye. They cantypes of embryos treated with BIO or LiCl (Figures 6B–
6G). When applied during early cleavage stage, LiCl be obtained from plants, mollusks, bacteria, and mam-
malian urine. A few years ago, we discovered their po-leads to a hyper dorso-anteriorization at the expense of
trunk and tail (anteriorized phenotype, Figure 6D). BIO tent action as protein kinase inhibitors, first on CDKs
[26] and later on GSK-3 (24). In this article, we reportphenocopies the LiCl effect in a dose-dependent man-
ner (Figures 6E and 6F), while MeBIO remains without that a minor modification (substitution on position 6)
leads to enhanced selectivity for GSK-3 over CDKs.effect (Figure 6C). The Wnt pathway can ectopically in-
duce dorsal genes, like the direct Wnt target siamois Compared to the nonsubstituted indirubins [26, 52], the
bromine substitution appears to impart increased global[48], and the Spemann organizer marker and siamois
target chordin [49]. RT-PCR analysis of animal cap ex- selectivity as seen from the lack of effects of 6-bromo-
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Figure 3. Structure of GSK-3-BIO Cocrystal
(A) Ribbon diagram showing the overall fold of the GSK-3-BIO complex. The BIO molecule is shown as a stick model with carbon atoms
colored light gray, oxygen atoms red, nitrogen atoms blue, and bromine in green. The position of the N terminus is indicated.
(B) A 2Fo-Fc omit density map of the BIO contoured at 2.
(C) LIGPLOT [65] interaction diagram for BIO. Hydrogen bonds are shown as dotted lines. Van der Waals contacts are shown as “hairy”
semicircles.
(D) Superposition of CDK2/cyclinA-I5S with GSK-3-BIO. The CDK complex is in green, and the GSK-3 complex is in gray. (A), (B), and (D)
were created with PyMol [66].
substituted indirubins on a large panel of kinases (Table to give access to further potent and selective inhibitors
of GSK-3. It should also provide the opportunity to im-1B) and from the affinity chromatography experiment
(Figure 2). The reasons behind this unexpected specific- prove the solubility of these hydrophobic compounds
and to improve their pharmacokinetic properties. Asity for GSK-3 became clear when the GSK-3/BIO and
CDK5/IO or CDK2/IO cocrystal structures were exam- many ATP-competitive kinase inhibitors bind by hy-
drophobic interactions within the ATP binding pocketined. Briefly, the bromine of BIO establishes a van der
Waals contact with the Leu132 residue of GSK-3. The of their kinase targets [53], they are bound to be rather
hydrophobic, poorly soluble compounds, and this pro-corresponding amino acid in CDK2 and CDK5 is a phe-
nylalanine, i.e., a bulkier residue, which would prohibit file needs to be improved for clinical applications.
Interestingly, indirubins were found to inhibit thethe binding of the bromine. In addition, the position 5
of indirubin could probably accommodate another small phosphorylation of Tyr276/Tyr216 (GSK-3/GSK-3) (Fig-
ure 5C), further contributing to the inactivation of GSK-3substitution compatible with binding to GSK-3 but not
to CDKs. A more extensive discussion of the structure/ activity. It is unlikely that GSK-3, a Ser/Thr kinase, phos-
phorylates itself on this Tyr residue. Furthermore, a ki-activity relationship of indirubins will be presented else-
where (P.M. et al., unpublished data). We feel that further nase-inactive GSK-3 mutant was phosphorylated on
Tyr216 following apoptotic stimuli [11]. It is possible thatexploration of the 5 and 6 positions in indirubins is likely
Tyrian Purple-Derived Indirubins Inhibit GSK-3
1261
Figure 4. Structure of CDK5/p25-IO Cocrystal
(A) Ribbon diagram showing the overall fold of the CDK5/p25-IO complex. The IO molecule is shown in a ball-and-stick representation with
carbon atoms colored light gray, oxygen atoms red, and nitrogen atoms blue. The position of the N and C termini are indicated. The figure
was created with the program RIBBONS [67].
(B) A 2Fo-Fc omit electron density map for IO contoured at one time the root mean square deviation (1 ) of the map.
(C) Schematic diagram of the interaction of IO with CDK5/p25. Hydrogen bonds are shown as dotted lines. Van der Waals contacts are shown
as “hairy” semicircles. The diagram was created with the program LIGPLOT [65].
(D) Superposition of CDK5/p25-IO and CDK2/cyclinA-I5S obtained considering the kinase residues adjacent to the inhibitors. IO is colored
as in (A), while atoms in CDK2/cyclinA-I5S are colored green.
Figure 5. BIO Is a Selective GSK-3 Inhibitor
in Cell Cultures
(A) BIO inhibits the phosphorylation of
-catenin on GSK-3-specific sites. Cos-1
cells were untreated (mock) or exposed to
5 M IO, BIO, MeBIO, or 20 mM LiCl for 24 hr.
Proteins were then separated by SDS-PAGE
followed by Western blotting with antibodies
directed (top to bottom) against -catenin,
dephospho--catenin, GSK-3, and actin (load-
ing control). A nonspecific band detected with
the dephospho--catenin was used as an ad-
ditional loading control.
(B) Independence from AhR. Cell lines defi-
cient either for AhR or ARNT were exposed
to 10 M BIO and 50 M MeBIO for 24 hr.
Western blots were then made with antibod-
ies directed against -catenin and actin (loading control).
(C) Indirubins inhibit the tyrosine phosphorylation of GSK-3. SH-SY5Y cells were untreated (mock) or exposed to 1 M IO, MeIO, BIO, and
MeBIO for 12 hr. Proteins were then separated by SDS-PAGE followed by Western blotting with antibodies directed (top to bottom) against
total GSK-3, phospho Tyr276 (GSK-3)/Tyr216 (GSK-3), dephospho--catenin, and total -catenin.
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Figure 6. BIO Activates the Maternal Wnt Signaling Pathway in Xenopus laevis Embryos
(A) Diagram of the Wnt pathway in Xenopus. The site of action and mechanism for Wnt pathway activation are indicated. Green arrows indicate
positive effects, and red capped lines indicate negative ones.
(B) Untreated embryo, tadpole stage.
(C–G) Activation of the maternal Wnt pathway. Embryos were treated with the specified reagents before stage 8, and were allowed to develop
to tadpole stage. (C), embryos treated with 50 M of the inactive MeBIO are unchanged; (D) embryos treated with 0.3 M LiCl are anteriorized.
(E)–(G) demonstrate the dose-dependent effect of BIO. The intensity of the anteriorized phenotype increases with BIO concentration (50 M,
15 M, and 5 M, respectively).
(H) BIO activates ectopically the dorsal genes siamois and chordin, and epistasis analysis of their induction is consistent with in vivo inhibition
of GSK-3. RT-PCR of animal cap explants for the direct Wnt target gene siamois and the siamois target chordin with odc as loading control.
Li (0.3 M) and BIO (50 M) induce both siamois and chordin (lanes 3 and 4), which are absent in explants from untreated embryos (lane 2).
The GSK-3-independent inhibitor of the Wnt pathway DN-Xtcf-3 completely blocks the effect of Li (lane 6) and partially blocks the effect of
BIO (lane 7). The GSK-3-dependent inhibitor axin fails to block either Li (lane 9, compare to lane 3) or BIO (lane 10, compare to lane 4).
(I) BIO is a potent anterior and neural tissue inducer in animal cap explants. RT-PCR of animal cap explants for general neural (nrp1), anterior
neural (otx2), anterior tissue (cement gland marker xag1), midbrain (en2), and posterior neural (xhoxb9) markers. Lane 1 is a control embryo,
stage 16. Cap explants from untreated embryos do not express anterior or neural markers (lane 2). Animal cap explants from embryos treated
with BIO (lanes 6 and 7) express anterior neural markers more effectively than explants from embryos treated with LiCl (lanes 4 and 5) or
injected with RNA for the neural inducer noggin (lane 3). odc is a loading control marker.
the presence of indirubin in the ATP binding pocket of simply by introducing a methyl substitution on N1. These
compounds could be useful as controls but also asGSK-3 prohibits access to the tyrosine kinase responsi-
ble for Tyr216/276 phosphorylation. This steric hin- molecular sinks to neutralize nonkinase, indirubin bind-
ing proteins such as AhR. Unfortunately, the 1-methyl-drance may thus lead to a secondary inhibitory effect
on GSK-3. Another possibility is that the tyrosine kinase ated indirubins are rather active AhR agonists, and this
should be taken into account. So far, we have beenphosphorylating Tyr276/Tyr216 is downstream of GSK3/
GSK-3 in a feedback pathway, such that inhibition of unable to generate indirubin analogs that are active on
the kinases but totally inactive on AhR (M.K. et al., sub-GSK-3 by indirubins prevents the activation of the GSK-3
kinase that acts upon these tyrosine residues. mitted).
There is a strong need for pharmacological inhibitorsFrom the diverse available kinase/indirubin cocrystal
structures, we were able to generate indirubins (such as to probe the multiple functions of GSK-3 in cell physiol-
ogy. Only a limited number of such inhibitors are avail-MeIO and MeBIO) that are unable to inhibit the kinases,
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1H-13C NMR experiments were performed using standard Brukerable (reviewed in [21, 54, 55]), and their selectivity is
microprograms. CI-MS spectra were determined on a Finnigan GCQusually uncharacterized. BIO, MeBIO, and related indi-
Plus ion-trap mass spectrometer using CH4 as the CI ionizationrubins thus provide potent, micromolar pharmacological
reagent. Medium pressure liquid chromatography (MPLC) was per-
tools, as well as relevant inactive controls, to investigate formed with a Bu¨chi model 688 apparatus on columns containing
the cellular functions of GSK-3. However, in addition Si gel 60 Merck (20–40 m). Thin layer chromatography (TLC) was
performed on plates coated with Si gel 60 F254 Merck, 0.25 mm. Allto these indirubins the parallel use of other reported,
the compounds gave satisfactory combustion analyses (C, H, N,structurally unrelated, GSK-3 inhibitors would help to
within  0.4% of calculated values).probe the involvement of GSK-3 in cellular processes.
Biological MaterialIn this context, the combined use of kenpaullone [54]
The marine mollusk Hexaplex trunculus L. was collected in shallow
and lithium has been recently recommended [52]. waters in the Saronikos gulf near the island of Salamina (Greece).
Pharmacological inhibitors of GSK-3 are being devel- Voucher specimens are deposited in the collection of the Goulandris
Natural History Museum.oped as potential drugs against diabetes, neurodegen-
Extraction and Isolation of Indirubinserative diseases, cancer, inflammation, and infectious
The mollusks (60 kg), after removal of the shells, were exposed todiseases. We are currently interested in the implication
sunlight for 6 hr, lyophilized, and extracted with CH2Cl2 (3  15 literof GSK-3 in neurodegenerative disorders, which are as-
for 48 hr). The CH2Cl2 extract (162 g) was subjected to vacuum liquidsociated with neuronal cell death, such as Alzheimer’s chromatography on silica gel 60H with increasing polarity mixtures
disease (see Introduction; reviewed in [56]). Indeed, the of cyclohexane/CH2Cl2 (from 100:0 to 0:100) to afford 45 fractions
of 500 ml. Fractions 34–45 were rechromatographed with vacuumtwo main diagnostic features of Alzheimer’s disease,
liquid chromatography on silica gel 60H with increasing polarity-amyloid toxicity/agregation and tau hyperphosphory-
mixtures of cyclohexane/EtOAc (from 95:5 to 0:100) to afford 40lation/aggregation, are both directly linked to GSK-3
fractions of 300 ml. Fractions 36–39 were submitted to medium(reviewed in [4, 56, 57]). -amyloid aggregates induce
pressure liquid chromatography (MPLC) using a cyclohexane/EtOAc
the activation of GSK-3 and apoptotic cell death, and gradient (from 95:5 to 85:15) to give indirubin (1) (3.5 mg), 6-bro-
this is prevented by lithium ([58–60] and references moindirubin (2) (5.5 mg), 6-bromoindirubin (3) (2.8 mg), and 6,6-
dibromoindirubin (4) (3 mg).therein). Very recently, a role for GSK-3 in the produc-
General Synthetic Procedurestion of -amyloid peptides was demonstrated [61]. Inhi-
The synthesis of indirubin precursors and indirubins is described inbition of GSK-3 by lithium, kenpaullone, or RNAi resulted
detail elsewhere (P.M. et al., unpublished data). Indirubin (1) wasin a dramatic decrease in -amyloid production [61].
prepared from isatin and 3-acetoxyindol. 6-bromoindirubin (2) was
Aggregation of the microtubule binding protein tau is prepared from isatin and 3-acetoxy-6-bromoindol. 6-bromoindirubin
directly linked to hyperphosphorylation by two main en- (3) was prepared from 6-bromoisatin and 3-acetoxyindol. 6,6-Dibro-
moindirubin (4) was prepared from 6-bromoisatin and 3-acetoxy-zymes, CDK5/p25 and GSK-3. GSK-3 is one of the en-
6-bromoindol. 6-bromo-1-methylindirubin (10) was prepared fromzymes responsible for the appearance of Alzheimer’s
6-bromo-1-methylisatin and 3-acetoxyindol. Indirubin-3-oxime (5)disease-specific epitopes in tau [4, 62, 63]. Altogether,
(IO), 6-bromoindirubin-3-oxime (6), 6-bromoindirubin-3-oxime (7)these data support the validity of evaluating pharmaco-
(BIO), 6,6-dibromoindirubin-3-oxime (8), 1-methylindirubin-3-oxime
logical inhibitors of GSK-3 for the treatment of Alzhei- (9) (MeIO),and 1-methyl-6-bromoindirubin-3-oxime (11) (MeBIO) were
mer’s disease. The cocrystal structure of GSK-3 and prepared from the corresponding indirubins (1, 2, 3, 4, 1-methylindi-
rubin, 10) and hydroxylamine hydrochloride.an inhibitor presented here provides tools for molecular
modeling of new inhibitors.
Kinase Assays
The preparation and assay of protein kinases is described in theSignificance
Supplemental Data (http://www.chembiol.com/cgi/content/full/10/
12/1255/DC1).
The bis-indole indirubin has been known for over a
century as a contaminant of the plant-derived indigo Affinity Chromatography on Immobilized Indirubin
dye. It also constitutes the active ingredient of a tradi- The immobilization of indirubin on a matrix is described in the Sup-
plemental Data (see URL above).tional Chinese medicinal recipe used to treat chronic
Preparation of Extractsmyelocytic leukemia. We here show that 6-brominated
Pork brains were obtained from a local slaughterhouse and directlyindirubins extracted from another natural source, the
homogenized and processed for affinity chromatography or storedMollusk Hexaplex trunculus, provide an unexpected
at 80C prior to use. Tissues were weighed, homogenized, and
scaffold to generate potent kinase inhibitors selective sonicated in homogenization buffer (2 ml per g of material). Homoge-
for GSK-3 as compared to CDKs. We also provide nates were centrifuged for 10 min at 14,000 g at 4C. The superna-
tant was recovered, assayed for protein content (BIO-Rad assay),cocrystal structures of indirubins in complex with
and immediately loaded batchwise on the affinity matrix.GSK-3 and CDK5. These 6-brominated indirubins may
Affinity Chromatography of Interacting Proteinsbe useful as pharmacological tools in cell biology. Fur-
Just before use, 20 l of packed indirubin beads were washed withthermore, they could be used to investigate the effects
1 ml of bead buffer (50 mM Tris [pH 7.4], 5 mM NaF, 250 mM NaCl,
of GSK-3 modulation on the long-term outcome of 5 mM EDTA, 5 mM EGTA, 0.1% Nonidet P-40, 10 g leupeptin/ml,
neurodegenerative diseases such as Alzheimer’s dis- 10 g aprotinin/ml, 10 g soybean trypsin inhibitor/ml, and 100 M
benzamidine) and resuspended in 600 l of this buffer. The tissueease and other diseases such as diabetes.
extract supernatant (4 mg total protein) was then added in the pres-
ence or absence of 20 M BIO; the tubes were rotated at 4C forExperimental Procedures
30 min. After a brief spin at 10,000  g and removal of the superna-
tant, the beads were washed four times with bead buffer beforeNatural Products Extraction and Chemistry
General Chemistry Experimental Procedures addition of 50 l of 2 Laemmli sample buffer.
Electrophoresis and Western BlottingNMR spectra were recorded on Bruker DRX 400 and Bruker AC 200
spectrometers (1H [400 and 200 MHz] and 13C [50 MHz]); chemical Following heat denaturation for 3 min, the proteins bound to the
indirubin matrix were separated by 10% SDS-PAGE (0.7 mm thickshifts are expressed in ppm downfield from TMS. The 1H-1H and the
Chemistry & Biology
1264
gels) followed by immunoblotting analysis or silver staining. Silver 2. Grimes, C.A., and Jope, R.S. (2001). The multifaceted roles of
glycogen synthase kinase 3 in cellular signaling. Prog. Neuro-staining was performed according to a “home recipe” (fixative: 250
l 37% formaldehyde in 250 ml 50% methanol; rinsing with milliQ biol. 65, 391–426.
3. Eldar-Finkelman, H. (2002). Glycogen synthase kinase 3: anwater containing 35 M DTT, followed by 0.1% AgNO3 in milliQ
water (w/v); developer: 12 g Na2CO3 in 400 ml milliQ water containing emerging therapeutic target. Trends Mol. Med. 8, 126–132.
4. Kaytor, M.D., and Orr, H.T. (2002). The GSK3 signaling cascade200l 37% formaldehyde). For immunoblotting, proteins were trans-
ferred to 0.1 m nitrocellulose filters (Schleicher and Schuell). These and neurodegenerative disease. Curr. Opin. Neurobiol. 12,
275–278.were blocked with 5% lowfat milk in Tris-Buffered Saline-Tween-
20 (TBST), incubated with anti-GSK-3/ (mouse monoclonal anti- 5. Doble, B.W., and Woodgett, J.R. (2003). GSK-3: tricks of the
GSK-3/ antibody [KAM-ST002C], from StressGen Biotechnolog- trade for a multi-tasking kinase. J. Cell Sci. 116, 1175–1186.
ies Corp.; 1:1000; 1 hr), and analyzed by Enhanced Chemilumines- 6. Ding, Y., and Dale, T. (2002). Wnt signal transduction: kinase
cence (ECL, Amersham). cogs in a nano-machine. Trends Biochem. Sci. 27, 327–329.
7. Li, X., Bijur, G.N., and Jope, R.S. (2002). Glycogen synthase
Effects of Indirubins on Level and Phosphorylation kinase-3beta, mood stabilizers, and neuroprotection. Bipolar
of -Catenin and GSK-3 in Cell Lines Disord. 4, 137–144.
COS1, Hepa (wild-type, CEM/LM AhR deficient and ELB1 ARNT 8. Bijur, G.N., and Jope, R.S. (2001). Proapoptotic stimuli induce
deficient), or SH-SY5Y cells were grown in 6 cm culture dishes in nuclear accumulation of glycogen synthase kinase-3 beta. J.
Dulbecco’s Modified Medium (DMEM) containing 10% fetal bovine Biol. Chem. 276, 37436–37442.
serum (Invitrogen). For treatment, IO (5M), BIO (5 or 10M), MeBIO 9. Crowder, R.J., and Freeman, R.S. (2000). Glycogen synthase
(5 or 50 M), LiCl (20 or 40 mM), or mock solution (DMSO, 0.5% kinase-3 beta activity is critical for neuronal death caused by
final concentration) was added to medium when cell density reached inhibiting phosphatidylinositol 3-kinase or Akt but not for death
70% confluence. After 12 (SH-SY5Y) or 24 hr, the cells, while caused by nerve growth factor withdrawal. J. Biol. Chem. 275,
still in plate, were lysed with lysis buffer (1% SDS, 1 mM sodium 34266–34271.
orthovanadate, 10 mM Tris [pH 7.4]). The lysate was passed several 10. Culbert, A.A., Brown, M.J., Frame, S., Hagen, T., Cross, D.A.,
times through a 26G needle, centrifuged at 10,000  g for 5 min, Bax, B., and Reith, A.D. (2001). GSK-3 inhibition by adenoviral
and adjusted to equal protein concentration. About 8 g of each FRAT1 overexpression is neuroprotective and induces Tau de-
sample was loaded for immunoblotting. Enhanced chemilumines- phosphorylation and beta-catenin stabilisation without eleva-
cence (PerkinElmer) was used for detection. The following primary tion of glycogen synthase activity. FEBS Lett. 507, 288–294.
antibodies were used: mouse anti--catenin CT (Upstate Biotech- 11. Bhat, R.V., Shanley, J., Correll, M.P., Fieles, W.E., Keith, R.A.,
nolgies, Clone 7D8, recognizes total -catenin), mouse anti-phos- Scott, C.W., and Lee, C.M. (2000). Regulation and localization
pho--catenin (Upstate Biotechnologies, Clone 8E7, recognizes of tyrosine216 phosphorylation of glycogen synthase kinase-
dephosphorylated -catenin) [41], mouse anti-GSK-3  (BD Trans- 3beta in cellular and animal models of neuronal degeneration.
duction Laboratories, 610201), mouse anti-GSK-3 phosphoTyr216 Proc. Natl. Acad. Sci. USA 97, 11074–11079.
(Transduction Laboratories), rabbit anti-AhR (Aryl hydrocarbon re- 12. Cross, D.A., Culbert, A.A., Chalmers, K.A., Facci, L., Skaper,
ceptor) (BIOMOL Research Laboratories, SA-210), and rabbit anti- S.D., and Reith, A.D. (2001). Selective small-molecule inhibitors
actin (Sigma, A5060). of glycogen synthase kinase-3 activity protect primary neurones
from death. J. Neurochem. 77, 94–102.
Effects of Indirubins on Xenopus Embryos 13. Bijur, G.N., De Sarno, P., and Jope, R.S. (2000). Glycogen syn-
Handling of Embryos thase kinase-3beta facilitates staurosporine- and heat shock-
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tured in 0.1 MMR and staged [64]. For lithium treatment, embryos 7583–7590.
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8. Embryos were subsequently allowed to develop to tadpole stage. 44708.
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Note Added in Proof
While this work was in press, the crystal structure of GSK-3 in
complex with several inhibitors was reported: the thiazole AR-
A014418 [68] and staurosporine, IO, alsterpaullone, and the anilino-
maleimide I-5 [69].
